Chapurlat R, Meunier P J
Service de Rhumatologie et de Pathologie Osseuse, Hôpital Edouard Herriot, Lyon.
Rev Chir Orthop Reparatrice Appar Mot. 1998 Nov;84(8):743-51.
Paget's disease of bone, bone fibrous dysplasia and osteoporosis are characterized by abnormal bone remodeling, and frequently imply intervention of orthopedists. Recent significant medical therapeutics improvements have been obtained with the use of bisphosphonates. Theses drugs decrease bone remodeling. In Paget's disease, bisphosphonates relieve bone pain, allow lytic areas refilling and decrease complications risk with normal bone formation. In fibrous dysplasia, bone pain is alleviated, osteolytic areas are refilled and cortices are widened. In postmenopausal osteoporosis, bisphosphonates increase bone mineral density, and reduce very significantly the subsequent risk of vertebral, femoral and lower forearm fractures. Bisphosphonates are a breakthrough in Paget's disease of bone, fibrous dysplasia of bone and osteoporosis.
骨佩吉特病、骨纤维发育不良和骨质疏松症的特征是骨重塑异常,常需要骨科医生进行干预。最近,使用双膦酸盐类药物在医学治疗方面取得了显著进展。这些药物可减少骨重塑。在佩吉特病中,双膦酸盐可缓解骨痛,使溶骨区重新填充,并降低正常骨形成时的并发症风险。在骨纤维发育不良中,可减轻骨痛,填充溶骨区并使皮质增宽。在绝经后骨质疏松症中,双膦酸盐可增加骨矿物质密度,并显著降低随后发生椎体、股骨和前臂下端骨折的风险。双膦酸盐是骨佩吉特病、骨纤维发育不良和骨质疏松症治疗方面的一项突破。